{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:42:50Z","timestamp":1790473370055,"version":"4.1.0"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2020,12,30]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Lipid control is essential in type 2 diabetes mellitus (T2DM). The aim of this study is to investigate factors associated with lipid therapy adherence and achievement of goals in real-life setting among patients with recently diagnosed T2DM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Research design and methods<\/jats:title>\n                  <jats:p>This is a longitudinal analysis in a center of comprehensive care for patients with diabetes. We include patients with T2DM, &lt;5 years of diagnosis, without disabling complications (eg, amputation, myocardial infarct, stroke, proliferative retinopathy, glomerular filtration rate &lt;60\u2009mL\/min\/m<jats:sup>2<\/jats:sup>) and completed 2-year follow-up. The comprehensive diabetes care model includes 9 interventions in 4 initial visits and annual evaluations. Endocrinologists follow the clinic\u2019s guideline and adapt therapy to reach risk-based treatment goal. The main outcome measures were the proportion of patients meeting low-density lipoprotein cholesterol (c-LDL) (&lt;100\u2009mg\/dL) and triglycerides (&lt;150\u2009mg\/dL) and proportion of patients taking statin, fibrate or combination at baseline, 3 months and annual evaluations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 288 consecutive patients (54\u00b19 years, 53.8% women), time since T2DM diagnosis 1 (0\u20135)\u2009year. Baseline, 10.8% patients were receiving statin therapy (46.5% moderate-intensity therapy and 4.6% high-intensity therapy), 8.3% fibrates and 4.2% combined treatment. The proportion of patients with combined treatment increased to 41.6% at 3 months, decreased to 20.8% at 1 year and increased to 38.9% at 2 years of evaluation. Patients receiving treatment met LDL and triglycerides goals at 3 months (17% vs 59.7%, relative ratio (RR)=0.89, 95% CI 0.71 to 1.12), at 1 year (17% vs 26.7%, RR=0.62, 95% CI 0.41 to 0.95) and at 2 years (17% vs 29.9%, RR=0.63, 95% CI 0.43 to 0.93). Main reasons for medication suspension: patient considered treatment was not important (37.5%) and other physician suspended treatment (31.3%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>88.2% of patients with T2DM required lipid-lowering drugs. Education for patients and physicians is critical to achieve and maintain diabetes goals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"NCT02836808\">NCT02836808<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjdrc-2020-001891","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T11:40:39Z","timestamp":1612957239000},"page":"e001891","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Clinician prescription of lipid-lowering drugs and achievement of treatment goals in patients with newly diagnosed type 2 diabetes mellitus"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct02836808","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02836808","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-4938","authenticated-orcid":false,"given":"Ana Cristina","family":"Garc\u00eda-Ulloa","sequence":"first","affiliation":[{"name":"Centro de Atenci\u00f3n Integral del Paciente con Diabetes (CAIPaDi), Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"},{"name":"Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lechuga-Fonseca","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola Mabel","family":"Del Razo-Olvera","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n de Enfermedades Metab\u00f3licas, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8517-0241","authenticated-orcid":false,"given":"Carlos Alberto","family":"Aguilar-Salinas","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n de Enfermedades Metab\u00f3licas, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"},{"name":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"name":"Direcci\u00f3n de Nutrici\u00f3n, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla Ivette","family":"Galaviz","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8621-5405","authenticated-orcid":false,"given":"K M Venkat","family":"Narayan","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3080-8708","authenticated-orcid":false,"given":"Sergio","family":"Hern\u00e1ndez-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Centro de Atenci\u00f3n Integral del Paciente con Diabetes (CAIPaDi), Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"},{"name":"Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"2025073111540606000_9.1.e001891.1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s13300-016-0167-x","article-title":"Diabetes dyslipidemia","volume":"7","author":"Schofield","year":"2016","journal-title":"Diabetes Ther"},{"key":"2025073111540606000_9.1.e001891.2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2017-311606"},{"key":"2025073111540606000_9.1.e001891.3","first-page":"703","article-title":"Associations between statin adherence level, health care costs, and utilization","volume":"20","author":"Zhao","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"2025073111540606000_9.1.e001891.4","first-page":"266","article-title":"Adherence pattern of lipid lowering drugs in a tertiary care hospital","volume":"26","author":"Khatun","year":"2017","journal-title":"Mymensingh Med J"},{"key":"2025073111540606000_9.1.e001891.5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01818.x"},{"key":"2025073111540606000_9.1.e001891.6","first-page":"38","article-title":"Cardiovascular risk reduction: past, present and future in Mexico","volume":"2","author":"Peralta","year":"2018","journal-title":"Ann Clin Hypertens"},{"key":"2025073111540606000_9.1.e001891.7","doi-asserted-by":"publisher","DOI":"10.1590\/S0036-36342010000700008"},{"key":"2025073111540606000_9.1.e001891.8","doi-asserted-by":"publisher","DOI":"10.21149\/8566"},{"key":"2025073111540606000_9.1.e001891.9","first-page":"115.e","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidemias","volume":"70","author":"Catapano","year":"2017","journal-title":"Rev Esp Cardiol"},{"key":"2025073111540606000_9.1.e001891.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.003"},{"key":"2025073111540606000_9.1.e001891.11","first-page":"485","article-title":"Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study","volume":"21","author":"Blackburn","year":"2005","journal-title":"Can J Cardiol"},{"key":"2025073111540606000_9.1.e001891.12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5694\/j.1326-5377.1996.tb94138.x","article-title":"Apparent discontinuation rates in patients prescribed lipid-lowering drugs","volume":"164","author":"Simons","year":"1996","journal-title":"Med J Aust"},{"key":"2025073111540606000_9.1.e001891.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.18.1458"},{"key":"2025073111540606000_9.1.e001891.14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jacl.2016.12.007","article-title":"Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome","volume":"11","author":"Turner","year":"2017","journal-title":"J Clin Lipidol"},{"key":"2025073111540606000_9.1.e001891.15","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-3669-6"},{"key":"2025073111540606000_9.1.e001891.16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2174\/1872214808999141110155515","article-title":"Innovative models for the empowerment of patients with type 2 diabetes: the CAIPaDi program","volume":"8","author":"Hern\u00e1ndez-Jim\u00e9nez","year":"2014","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"2025073111540606000_9.1.e001891.17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.diabres.2019.04.009","article-title":"Long-Term effectiveness of a type 2 diabetes comprehensive care program. The CAIPaDi model","volume":"151","author":"Hern\u00e1ndez-Jim\u00e9nez","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"2025073111540606000_9.1.e001891.18","unstructured":"Hern\u00e1ndez-Jim\u00e9nez S , Aguilar-Salinas CA , Garc\u00eda-Ulloa AC . Algoritmo de atenci\u00f3n cl\u00ednica. M\u00e9xico. plan Estrat\u00e9gico sectorial para La Difusi\u00f3n E Implementaci\u00f3n de Gu\u00edas de Pr\u00e1ctica Cl\u00ednica. diabetes mellitus tipo 2. Secretar\u00eda de Salud, SEDENA, SEMAR 2018 http:\/\/www.incmnsz.mx\/CAIPaDi\/algoritmo.pdf 2018."},{"key":"2025073111540606000_9.1.e001891.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.002"},{"key":"2025073111540606000_9.1.e001891.20","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-S010"},{"key":"2025073111540606000_9.1.e001891.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.4.455"},{"key":"2025073111540606000_9.1.e001891.22","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.5603\/KP.a2018.0154","article-title":"Cardiovascular diseases prevention in Poland: results of WOBASZ and WOBASZ II studies","volume":"76","author":"Piwo\u0144ska","year":"2018","journal-title":"Kardiol Pol"},{"key":"2025073111540606000_9.1.e001891.23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.endinu.2018.08.014","article-title":"Determinantes de la inercia en El tratamiento hipolipidemiante de pacientes Con diabetes mellitus tipo 2","volume":"66","author":"Garc\u00eda D\u00edaz","year":"2019","journal-title":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"},{"key":"2025073111540606000_9.1.e001891.24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.18.1458"},{"key":"2025073111540606000_9.1.e001891.25","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3181c132ad"},{"key":"2025073111540606000_9.1.e001891.26","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2003.026187"},{"key":"2025073111540606000_9.1.e001891.27","doi-asserted-by":"crossref","first-page":"722","DOI":"10.18553\/jmcp.2014.20.7.722","article-title":"Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis","volume":"20","author":"Vegter","year":"2014","journal-title":"JMCP"},{"key":"2025073111540606000_9.1.e001891.28","doi-asserted-by":"publisher","DOI":"10.1177\/1741826711407010"},{"key":"2025073111540606000_9.1.e001891.29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-019-0974-y","article-title":"Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy","volume":"18","author":"Yan","year":"2019","journal-title":"Lipids Health Dis"},{"key":"2025073111540606000_9.1.e001891.30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.5144\/0256-4947.2017.276","article-title":"Utilization and adherence to guideline-recommended lipid-lowering therapy at an academic medical center","volume":"37","author":"Alburikan","year":"2017","journal-title":"Ann Saudi Med"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2020-001891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T18:54:15Z","timestamp":1753988055000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2020-001891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,2,10]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/bmjdrc-2020-001891"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2020-001891","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}